Innovent Biologics-B (07630.HK) expects to incur a loss of approximately 81.7 million to 99.9 million yuan in the mid-term, which represents a year-on-year decrease of about 22% to 37%.

According to a news release from Zhitong Finance APP, InnoCare Pharma Limited (07630.HK) announced that, based on the preliminary assessment of the group's unaudited consolidated management accounts for the six months ending June 30, 2026 (the "relevant period") by the Board of Directors and the information currently available to the Board, the group expects to achieve approximately RMB 94.7 million to RMB 116 million in revenue during the relevant period, an increase of approximately 276% to 359% compared to approximately RMB 25.2 million for the six months ending June 30, 2025 (the "same period"); the loss for the period is expected to be approximately RMB 81.7 million to RMB 99.9 million, a decrease of approximately 37% to 22% compared to approximately RMB 129 million in the same period.